Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Market Reach
Latest News
GBMA kicks off hunt for new CEO
Leadership: As incumbent Belinda Wood winds up her involvement, the call has gone out for candidates but interested parties need to get their skates on.
Bayer wins top supplier award
Marketing: Wholesaler Sigma has given its 2017 supplier of the year award to Bayer, with AbbVie and Janssen winners in other categories.
Diabetes Day trips up Krispy Kreme
Reputation: It might have been World Diabetes Day on Tuesday but that didn't stop Krispy Kreme from running a massive doughnut promotion - to its ultimate embarrassment.
Pharma's gender equity report card tick
Workplace: The two industries in which Australian pharmaceutical companies sit were ranked among the best performers in the latest annual gender equity report card released today.
Imbruvica slapped with safety label
Medicines Safety: New safety risks including a possible link with cardiac deaths have been included in Janssen's Imbruvica product label, just two weeks before the cancer drug hits the PBS.
OTC painkiller row hits courts
Litigation: A turf battle is underway in the Federal Court between two OTC pain product marketers, each looking to fill the gap left by the up-scheduling of codeine.
Most Popular
Pharma employees hold the cards in 2017
Workplace: Australian pharma employees found themselves holding the power in 2017, a top recruiter has revealed in the second part of this Pharma in Focus series, with some staff more in demand than others.
2017 'Year of Disruption' for Aust pharma
Workplace: 2017 will be remembered as a 'year of disruption and volatility', a leading recruiter says in the first of a three part Pharma in Focus series looking at trends of the past 12 months.
AbbVie hit with first Humira copy
Pipeline: Australian registration has been secured for the first ever biosimilar of AbbVie's Humira, marking a potenial end to the reign of one of the biggest drugs ever to come to market.
Controversy pharma's 'elephant in the room'
Marketing: Pharma marketers need to address controversies surrounding products or risk losing credibility, a GP publication's marketing director has warned.
Aust's largest contract pharma factory to open in Sydney
Manufacturing: Acclaimed as the largest contract pharma factory in Australia, the new facility will open in Sydney next week while in Victoria a $2 million pharma deal has been inked with the state government .
Beware the digital gap, pharma staff warned
Employment: Digital proficiency has emerged as an essential skill for Australian pharma employees this year, but there's a 'skills gap' some say.
Innovation comes from the top: O'Doherty
Leadership: Even in a highly regulated environment there are opportunities to innovate, Abbvie's Kirsten O'Doherty has told a Sydney women's leadership conference.
Cancer ASX debut biggest since CSL
Companies: Telix Pharma hit the ASX with a market capitalisation of $128 million in the biggest listing of an Australian biotech since CSL.
FDA allows adherence tracker in pill
Market Access: A version of schizophrenia drug Abilify containing a digestible sensor that tracks when the drug has been taken has been approved in the US.
Bayer spends big on gene-linked cancer meds
Pipeline: Bayer is offering payments of more than USD1.5 billion to jointly commercialise new precision drugs targeting cancers based on their genes.
Pipeline Monitor
Bumper week for AZ
AstraZeneca has registered regulatory wins for cancer drug Faslodex and new asthma biologic Fasenra in a busy week for the Anglo-Swedish company.
Why health bureaucrats need to do yoga
As health bureaucrats mull over a unique funding deal slapped down on the table by a drug sponsor looking to find a new path to reimbursement, they may find learning a few yoga moves useful.
Approvals Action
Generics come for Novartis, Pfizer drugs
Multi-million dollar earners from Novartis and Pfizer were the targets of new generic registrations in a busy week on the ARTG.
Pipeline Monitor
Bayer starts Xarelto expansion bid
Bayer has filed the first regulatory submission to add an atherosclerosis indication to Xarelto as it aims to widen access for its cardio drug.
FREE Content
Events & Conferences
Pharma in Focus Jobs